ABSTRACT
Ten female patients with a history of recurrent aphthous lesions for at least 5 years with the lesions occurring regularly in the latter half at the menstrual cycle were treated with progestogen in the form of an intramuscular depot injection. Medroxyprogesterone acetate and gestronol hexanoate was used. All 10 patients were satisfied with the treatment; the side effects were few.
Subject(s)
Gestonorone Caproate/therapeutic use , Medroxyprogesterone/therapeutic use , Stomatitis, Aphthous/drug therapy , Adult , Clinical Trials as Topic , Delayed-Action Preparations , Drug Evaluation , Female , Gestonorone Caproate/administration & dosage , Gestonorone Caproate/adverse effects , Humans , Injections, Intramuscular , Medroxyprogesterone/administration & dosage , Medroxyprogesterone/adverse effects , Menstruation , Middle Aged , Recurrence , Stomatitis, Aphthous/etiologyABSTRACT
Depostat treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study the clinical effect on prostatic cancer was, however, disappointing when compared to the well established effect of orchiectomy. The therapeutic failure of Depostat might be related to the incomplete suppression of plasma testosterone compared to that observed after orchiectomy.
Subject(s)
Adenocarcinoma/drug therapy , Gestonorone Caproate/therapeutic use , Prostatic Neoplasms/drug therapy , Adenocarcinoma/therapy , Aged , Castration , Drug Evaluation , Gestonorone Caproate/administration & dosage , Gestonorone Caproate/adverse effects , Humans , Male , Middle Aged , Prostatic Neoplasms/therapy , Testosterone/bloodABSTRACT
A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramucularly every 7 days over a period of 2 to 3 months. The results showed definite subjective and objective improvement after treatment. Residual urine determination diminished significantly after therapy in 78% of the cases completing the study; uroflometry also showed improvement. There appeared to be some reduction in the degree of occlusion of the urethral lumen in at least 13(65%) out of 20 patients given follow-up cystopanendoscopy after 6 months. This result was further supported by improvement in urinary flow rates and uroflometrograms in the same patients. The only adverse effect of treatment noted was the development of impotency in 21 patients.
